Related Experiment Video
Updated: Jan 14, 2026

Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
Ligustilide alleviates the mitophagy and anxiety-like behavior produced by nighttime lighting
Chenyi Gao1, Keshu Liu2, Cuiping Qi3
1Department of Anesthesiology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, 315040, China; Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Background:
Artificial light at night (ALAN) is an emerging environmental pollutant that disrupts circadian rhythms and increases the risk of neuropsychiatric disorders. Mitochondrial dysfunction and aberrant mitophagy are implicated in ALAN-induced anxiety-like behaviors, yet the underlying mechanisms remain elusive. Plant-derived compounds represent a promising avenue for neuroprotection.
Purpose:
This study aimed to explore the therapeutic potential of Ligustilide (LIG)-a natural dihydrophthalide compound extracted from Ligusticum chuanxiong hort (Rhizoma Chuanxiong) and Angelica sinensis (Oliv)-in alleviating ALAN-induced anxiety-like behavior, focusing on the novel mechanistic link between mitophagy modulation and PI3K-AKT pathway regulation to protect mitochondrial and synaptic integrity.
Methods:
Male mice were exposed to ALAN to induce anxiety-like behaviors, assessed using the elevated plus maze, novelty-suppressed feeding, marble burying, and open field tests. LIG (10 and 30 mg/kg, i.p.) was administered daily for 14 days. Mitochondrial morphology, synaptic integrity, mitophagy activity, and PI3K-AKT pathway activation in the cerebral cortex were examined by electron microscopy, immunofluorescence, and Western blotting.
Results:
ALAN exposure triggered significant anxiety-like behaviors, synaptic damage, and mitophagy hyperactivation, along with PI3K-AKT pathway overactivation. LIG treatment represents the first demonstration of a plant-derived compound simultaneously mitigating ALAN-induced mitophagy dysregulation and PI3K-AKT overactivation, thereby preserving neuronal ultrastructure and behavioral function.
Conclusion:
This study demonstrates that Ligustilide exerts neuroprotective effects against ALAN-induced neuronal injury, likely through modulation of mitophagy and PI3K-AKT signaling. Our findings provide novel insights into the mechanistic basis of ALAN neurotoxicity and suggest a promising therapeutic strategy grounded in traditional medicinal compounds.
Related Concept Videos
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Management of Insomnia
Antidepressant Drugs: MAOIs and Other Agents
Anxiolytic Drugs: Benzodiazepines and Buspirone
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

